Participating Companies


AM-Pharma B.V.
Re­sults from Ph 2 in 300+ pts de­mon­s­trat­ed im­prove­ment of 40%+ OS in re­cAP group. Ini­ti­at­ed Ph 3 in Q4 2020; TL safe­ty & fu­til­i­ty anal­y­sis on first 400 pts exp YE2021. Ex­pects to com­plete tgt en­roll­ment & an­nounce pri­mary end­point da­ta of 28-day all-cause mor­tal­i­ty in 2023. [more in­for­ma­tion]
CureVac AG [CVAC] US$14,556 MM MCap
Ger­man mR­NA com­pany with a di­ver­si­fied pipe­line; Ph 2a trial on­go­ing with COVID-19 vaccine can­di­date, CVn­CoV. Glob­al Ph 2b/3 trial en­rolling ap­prox. 30,000 par­ti­ci­pants ex­pect­ed to ini­ti­ate in 4Q20. Three other lead pro­grams in Ph 1: CV8102 (cu­ta­neous me­lano­ma, ade­noid­cys­tic car­ci­no­ma, squa­mous cell can­cer of skin, head & neck), CV9202 (NS­CLC) and CV7202 (Ra­bies). mR­NA-based anti­body de­liv­ery deal with Genmab (Dec'19). Other strate­g­ic part­n­er­ships with GSK and CRIS­PR Tx. Other com­pa­nies in the space: MR­NA, [more in­for­ma­tion]
Deutsche Bank AG [DB] US$23,473 MM MCap
Deutsche Bank’s ADR team is part of the Trust & Agen­cy Ser­vices busi­ness within the new­ly cre­at­ed Cor­po­rate Bank Di­vi­sion. Deutsche Bank was ap­point­ed as DR Bank for the largest Life Sci­ences sec­tor ADR IPO of 2019 with the $582m Nas­daq list­ing of Genmab A/S, con­firm­ing our po­si­tion as the lead­ing is­suer of cap­i­tal in the US ADR mar­kets. [more in­for­ma­tion]
Ernst & Young
[more in­for­ma­tion]
Evox Therapeutics
Ex­o­some-based drugs have the po­ten­tial to ad­dress some of the lim­i­ta­tions of pro­tein, anti­body and nu­cle­ic acid-based ther­a­pies by en­abling de­liv­ery to cells and tis­sues that are cur­rent­ly out of reach us­ing other drug de­liv­ery tech­nolo­gies, and Evox is lead­ing the de­vel­op­ment within this emerg­ing ther­a­peu­tic space. [more in­for­ma­tion]
Forward Pharma A/S [FWP] US$49 MM MCap
The Com­pany grant­ed to Bio­gen an ir­re­vo­ca­ble li­cense to all of its IP through the Li­cense Agree­ment and re­ceived from Bio­gen a non-re­fund­able cash fee of $1.25 bil­lion in Fe­bruary 2017, with the re­turn of EUR 917.7 mil­lion to share­hold­ers through a cap­i­tal re­duc­tion in Septem­ber 2017. [more in­for­ma­tion]
Goodwin Procter LLP
More than 1,000 cor­po­rate and liti­ga­tion at­tor­neys lev­er­age their spe­cif­ic ex­pe­ri­ence and as­sem­ble full-ser­vice teams to ad­vise clients in th­ese and ad­ja­cent in­dus­tries. [more in­for­ma­tion]
Immatics NV [IMTX] US$645 MM MCap
Im­mat­ics com­bines the dis­cov­ery of true tar­gets for can­cer im­munother­a­pies with the de­vel­op­ment of the right T cell re­cep­tors with the goal of en­abling a ro­bust and spe­cif­ic T cell re­sponse against th­ese tar­gets. We are com­mitt­ed to de­liv­er­ing the pow­er of T cells and to un­lock­ing new av­enues for pa­tients in their fight against can­cer. [more in­for­ma­tion]
Jefferies LLC [JEF] US$6,033 MM MCap
In late 2002, Jef­feries & Com­pany (U.S. The firm was found­ed in 1962 by Boyd Jef­feries and is head­quar­tered in New York and has of­fices world­wide. Leu­ca­dia Na­tio­n­al Cor­po­ra­tion ac­quired Jef­feries Group, LLC on March 1, 2013, on­the same day Jef­feries & Com­pany (U.S. [more in­for­ma­tion]
NautaDutilh
Found­ed in 1724, Nau­ta­Du­tilh has grown to be­come one of the largest in the Benelux with over 400 lawy­ers, civ­il law no­taries and tax ad­vis­ers at of­fices in Am­s­ter­dam, Brus­sels, Lon­don, Lux­em­bourg, New York and Rot­ter­dam. It al­lows Nau­ta­Du­tilh lawy­ers to deal with change, learn from new si­t­u­a­tions and think on their feet when solv­ing problems on be­half of our clients. [more in­for­ma­tion]
OpGen, Inc. [OPGN] US$40 MM MCap
Along with sub­si­diaries, Curetis GmbH and Ares Ge­net­ics GmbH, we are de­vel­op­ing and com­mer­cial­iz­ing molec­u­lar mi­cro­bi­ol­o­gy so­lu­tions help­ing to guide clini­cians with more rapid and ac­tion­able in­for­ma­tion about life threat­en­ing in­fec­tions to im­prove pa­tient out­comes, and de­crease the spread of in­fec­tions caused by mul­ti­drug-re­sis­tant mi­croor­ganisms, or MDROs. [more in­for­ma­tion]
Solebury Capital
Sole­bury Cap­i­tal LLC is a glob­al ad­vi­so­ry firm and reg­is­tered bro­k­er deal­er ex­clu­sive­ly fo­cused on the equi­ty cap­i­tal mar­kets. We pro­vide our cor­po­rate and fi­nan­cial spon­sor clients with in­de­pen­dent ad­vice, ex­pe­ri­enced judg­ment and tran­s­ac­tion ma­n­age­ment ser­vices – em­pow­er­ing them to make more ful­ly in­formed de­ci­sions at all points in the un­der­writ­ing pro­cess. [more in­for­ma­tion]
Solebury Trout
With al­most two de­cades of ex­pe­ri­ence in the biotech­nol­o­gy, phar­ma­ceu­ti­cal, med­i­cal tech­nol­o­gy and life sci­ence tech­nol­o­gy sec­tors, the Trout Group of­fers its clients the knowl­edge base need­ed to clar­i­fy in­vest­ment themes and lev­er­age key re­la­tion­ships for in­creased ex­po­sure to the prop­er au­di­ence. [more in­for­ma­tion]
SOTIO a.s.
SO­TIO pur­sues this goal through its the SO­TIO® in-house re­search and clin­i­cal de­vel­op­ment and re­lat­ed ser­vices, col­lab­o­ra­tions with ex­ter­nal part­n­ers, in-li­cens­ing deals, in­vest­ments and ac­qui­si­tions. [more in­for­ma­tion]
SVB Leerink
SVP Leerink is a full-ser­vice in­vest­ment bank that of­fers equi­ty re­search ser­vices to in­sti­tu­tio­n­al and re­tail in­ves­tors. The firm al­so of­fers in­sti­tu­tio­n­al sales/trad­ing, cor­po­rate fi­nance, and as­set ma­n­age­ment ser­vices. Leerink Part­n­ers, LLC al­so us­es anal­y­sis from ME­DA­Corp, a pri­vate­ly held com­pany that pro­vides biomed­i­cal con­sult­ing ser­vices. [more in­for­ma­tion]